Basic Information
RNALocate ID: | RLID:01001295 |
RNA Symbol: | hsa-miR-20a-5p |
Localization: | Cytoplasm |
RNA Information
RNA Name: | hsa-miR-20a |
RNA ID: | miRBase:MIMAT0000075 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 21695135 |
Tissue/Cell Line: | Cell line (HeLa) |
Method: | Microarray |
Heatmap showing the 57 miRNAs differentially expressed in HeLa cells from mitochondrial and cytosolic RNA. Three independent microarray profiling experiments (microarray n1, n2 and n3) are shown and reproducibly revealed 13 miRNAs enriched in mitochondrial RNA. Originally published in PLoS One. Bandiera S, et al, 2011. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | While 44 miRNAs showed a greater enrichment in the cytosolic Hy3-labeled RNA fraction, 13 miRNAs were significantly and reproducibly enriched in the mitochondrial Hy5-labeled RNA sample (ranging from 1.5- to 56-fold), namely hsa-miR-1973, hsa-miR-1275, hsa-miR-494, hsa-miR-513a-5p, hsa-miR-1246, hsa-miR-328, hsa-miR-1908, hsa-miR-1972, hsa-miR-1974, hsa-miR-1977, hsa-miR-638, hsa-miR-1978 and hsa-miR-1201 (Figure 5A). Data are collected from Figure 5. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001294 | Cytoplasm | Neural progenitor cells | 21363885 |
RLID:01001296 | Cytoplasm | HeLa cells | 23940654 |
RLID:01001297 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001298 | Mitochondrion | Myotube | 27396686 |
RLID:01001299 | Mitochondrion | Skeletal muscle cells | 27563705 |
RLID:01001300 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
RLID:01001301 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
RLID:01001302 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
RLID:01001303 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
RLID:01001304 | Nucleus | Colon adenocarcinoma cells | 20864815 |
RLID:11000737 | Exosome | Sera | 24978137 |
RLID:11000738 | Exosome | Human cervical carcinoma cell line (HeLa|SiHa) | 25760330 |
RLID:11000739 | Exosome | Glioblastoma cells | 19011622 |
RLID:11000740 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
RLID:11000741 | Exosome | Breast milk | 22211110 |
RLID:11000742 | Exosome | Brain tissue | 23382797 |
RLID:11000743 | Exosome | Plasma | 23663360 |
RLID:11000744 | Exosome | Human mast cell line (HMC-1) | 24009880 |
RLID:11000745 | Exosome | Serum | 25349172 |
RLID:11000746 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11000747 | Extracellular Vesicle | Liposarcoma cell lines (Lipo246|Lipo863|LPS141)|Preadipocytes | 28588009 |
RLID:11000748 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11000749 | Microvesicle | Glioblastoma cells | 19011622 |
RLID:11000750 | Microvesicle | Seminal plasma | 23539611 |
RLID:11000751 | Microvesicle | Hepatoma cells | 23771658 |
RLID-D:11000012 | Exosome | B lymphoblastoid cells|Chronic lymphocytic leukemia cells|Endothelial cells|Epithelial cells|Lymphoma tissue|Tongue tissue | |
RLID-D:11000274 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-20a-5p | Splenic marginal zone lymphoma | MNDR-E-MI-27697 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis chronic progressive | MNDR-E-MI-27698 |
MNDR | hsa-miR-20a-5p | Colorectal adenocarcinoma | MNDR-E-MI-27699 |
MNDR | hsa-miR-20a-5p | Oral squamous cell carcinoma | MNDR-E-MI-27700 |
MNDR | hsa-miR-20a-5p | Large cell neuroendocrine cancer | MNDR-E-MI-27701 |
MNDR | hsa-miR-20a-5p | Medulloblastoma | MNDR-E-MI-27702 |
MNDR | hsa-miR-20a-5p | B cell lymphoma of malt type | MNDR-E-MI-27703 |
MNDR | hsa-miR-20a-5p | High-grade serous ovarian carcinoma | MNDR-E-MI-27704 |
MNDR | hsa-miR-20a-5p | Autism spectrum disorder | MNDR-E-MI-27705 |
MNDR | hsa-miR-20a-5p | Lymphoma | MNDR-E-MI-27706 |
MNDR | hsa-miR-20a-5p | Lymphoma non-hodgkin | MNDR-E-MI-27707 |
MNDR | hsa-miR-20a-5p | Estrogen-receptor positive breast cancer | MNDR-E-MI-27708 |
MNDR | hsa-miR-20a-5p | Estrogen-receptor negative breast cancer | MNDR-E-MI-27709 |
MNDR | hsa-miR-20a-5p | Progesterone-receptor positive breast cancer | MNDR-E-MI-27710 |
MNDR | hsa-miR-20a-5p | Progesterone-receptor negative breast cancer | MNDR-E-MI-27711 |
MNDR | hsa-miR-20a-5p | Her2-receptor positive breast cancer | MNDR-E-MI-27712 |
MNDR | hsa-miR-20a-5p | Breast cancer luminal | MNDR-E-MI-27713 |
MNDR | hsa-miR-20a-5p | Niemann-pick disease type c | MNDR-E-MI-27714 |
MNDR | hsa-miR-20a-5p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-27715 |
MNDR | hsa-miR-20a-5p | B cell acute lymphoblastic leukemia | MNDR-E-MI-27716 |
MNDR | hsa-miR-20a-5p | Dermatomyositis | MNDR-E-MI-27717 |
MNDR | hsa-miR-20a-5p | Prostate cancer | MNDR-E-MI-27718 |
MNDR | hsa-miR-20a-5p | Gastric cancer | MNDR-E-MI-27719 |
MNDR | hsa-miR-20a-5p | Gastric lymphoma | MNDR-E-MI-27720 |
MNDR | hsa-miR-20a-5p | Alzheimer disease | MNDR-E-MI-27721 |
MNDR | hsa-miR-20a-5p | Intracranial aneurysm | MNDR-E-MI-27722 |
MNDR | hsa-miR-20a-5p | Bladder cancer | MNDR-E-MI-27723 |
MNDR | hsa-miR-20a-5p | Esophageal carcinoma | MNDR-E-MI-27724 |
MNDR | hsa-miR-20a-5p | Dysautonomia familial | MNDR-E-MI-27725 |
MNDR | hsa-miR-20a-5p | Primary biliary cirrhosis | MNDR-E-MI-27726 |
MNDR | hsa-miR-20a-5p | Leukemia | MNDR-E-MI-27727 |
MNDR | hsa-miR-20a-5p | Ataxia telangiectasia | MNDR-E-MI-27728 |
MNDR | hsa-miR-20a-5p | Huntington disease | MNDR-E-MI-27729 |
MNDR | hsa-miR-20a-5p | Chorea | MNDR-E-MI-27730 |
MNDR | hsa-miR-20a-5p | Cardiovascular disease | MNDR-E-MI-27731 |
MNDR | hsa-miR-20a-5p | Carotid stenosis | MNDR-E-MI-27732 |
MNDR | hsa-miR-20a-5p | Moyamoya disease | MNDR-E-MI-27733 |
MNDR | hsa-miR-20a-5p | Lung cancer | MNDR-E-MI-27734 |
MNDR | hsa-miR-20a-5p | Down syndrome | MNDR-E-MI-27735 |
MNDR | hsa-miR-20a-5p | Parkinson disease | MNDR-E-MI-27736 |
MNDR | hsa-miR-20a-5p | Niemann-pick disease | MNDR-E-MI-27737 |
MNDR | hsa-miR-20a-5p | Colon carcinoma | MNDR-E-MI-27738 |
MNDR | hsa-miR-20a-5p | Basal-like breast cancer | MNDR-E-MI-27739 |
MNDR | hsa-miR-20a-5p | Squamous cell carcinoma | MNDR-E-MI-27740 |
MNDR | hsa-miR-20a-5p | Thyroid cancer | MNDR-E-MI-27741 |
MNDR | hsa-miR-20a-5p | Pituitary neoplasms | MNDR-E-MI-27742 |
MNDR | hsa-miR-20a-5p | Pancreatic cancer | MNDR-E-MI-27743 |
MNDR | hsa-miR-20a-5p | Melanoma | MNDR-E-MI-27744 |
MNDR | hsa-miR-20a-5p | Lesch-nyhan syndrome | MNDR-E-MI-27745 |
MNDR | hsa-miR-20a-5p | Rectum adenocarcinoma | MNDR-E-MI-27746 |
MNDR | hsa-miR-20a-5p | Nephroblastoma | MNDR-E-MI-27747 |
MNDR | hsa-miR-20a-5p | Colon cancer | MNDR-E-MI-27748 |
MNDR | hsa-miR-20a-5p | Ischemic attack transient | MNDR-E-MI-27749 |
MNDR | hsa-miR-20a-5p | Colon adenocarcinoma | MNDR-E-MI-27750 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis | MNDR-E-MI-27751 |
MNDR | hsa-miR-20a-5p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-27752 |
MNDR | hsa-miR-20a-5p | Ovarian cancer | MNDR-E-MI-27753 |
MNDR | hsa-miR-20a-5p | Prostate adenocarcinoma | MNDR-E-MI-27754 |
MNDR | hsa-miR-20a-5p | Kidney cancer | MNDR-E-MI-27755 |
MNDR | hsa-miR-20a-5p | Endometriosis | MNDR-E-MI-27756 |
MNDR | hsa-miR-20a-5p | Carcinoma ductal breast | MNDR-E-MI-27757 |
MNDR | hsa-miR-20a-5p | Glioblastoma | MNDR-E-MI-27758 |
MNDR | hsa-miR-20a-5p | Astrocytoma | MNDR-E-MI-27759 |
MNDR | hsa-miR-20a-5p | Glioma | MNDR-E-MI-27760 |
MNDR | hsa-miR-20a-5p | Oligodendroglioma | MNDR-E-MI-27761 |
MNDR | hsa-miR-20a-5p | Central nervous system lymphoma | MNDR-E-MI-27762 |
MNDR | hsa-miR-20a-5p | Chordoma | MNDR-E-MI-27763 |
MNDR | hsa-miR-20a-5p | Amyotrophic lateral sclerosis | MNDR-E-MI-27764 |
MNDR | hsa-miR-20a-5p | Epilepsy temporal lobe | MNDR-E-MI-27765 |
MNDR | hsa-miR-20a-5p | Osteosarcoma | MNDR-E-MI-27766 |
MNDR | hsa-miR-20a-5p | Liposarcoma | MNDR-E-MI-27767 |
MNDR | hsa-miR-20a-5p | Meningioma | MNDR-E-MI-27768 |
MNDR | hsa-miR-20a-5p | Liver cancer | MNDR-E-MI-27769 |
MNDR | hsa-miR-20a-5p | Uterine cancer | MNDR-E-MI-27770 |
MNDR | hsa-miR-20a-5p | Gastric adenocarcinoma | MNDR-E-MI-27771 |
MNDR | hsa-miR-20a-5p | Pituitary adenoma | MNDR-E-MI-27772 |
MNDR | hsa-miR-20a-5p | Lung squamous cell carcinoma | MNDR-E-MI-27773 |
MNDR | hsa-miR-20a-5p | Carcinoma lung non-small-cell | MNDR-E-MI-27774 |
MNDR | hsa-miR-20a-5p | Lung adenocarcinoma | MNDR-E-MI-27775 |
MNDR | hsa-miR-20a-5p | Adrenocortical carcinoma | MNDR-E-MI-27776 |
MNDR | hsa-miR-20a-5p | Thyroid carcinoma | MNDR-E-MI-27777 |
MNDR | hsa-miR-20a-5p | Ovarian carcinoma | MNDR-E-MI-27778 |
MNDR | hsa-miR-20a-5p | Bladder urothelial carcinoma | MNDR-E-MI-27779 |
MNDR | hsa-miR-20a-5p | Pancreatic adenocarcinoma | MNDR-E-MI-27780 |
MNDR | hsa-miR-20a-5p | Brain stem cancer | MNDR-E-MI-27781 |
MNDR | hsa-miR-20a-5p | Cervical cancer | MNDR-E-MI-27782 |
MNDR | hsa-miR-20a-5p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-27783 |
MNDR | hsa-miR-20a-5p | Kidney renal clear cell carcinoma | MNDR-E-MI-27784 |
MNDR | hsa-miR-20a-5p | Kidney renal papillary cell carcinoma | MNDR-E-MI-27785 |
MNDR | hsa-miR-20a-5p | Clear cell renal cell carcinoma | MNDR-E-MI-27786 |
MNDR | hsa-miR-20a-5p | Biliary tract cancer | MNDR-E-MI-27787 |
MNDR | hsa-miR-20a-5p | Pancreatic carcinoma | MNDR-E-MI-27788 |
MNDR | hsa-miR-20a-5p | Cholangiocarcinoma | MNDR-E-MI-27789 |
MNDR | hsa-miR-20a-5p | Esophageal cancer | MNDR-E-MI-27790 |
MNDR | hsa-miR-20a-5p | Lung small cell carcinoma | MNDR-E-MI-27791 |
MNDR | hsa-miR-20a-5p | Head and neck squamous cell carcinoma | MNDR-E-MI-27792 |
MNDR | hsa-miR-20a-5p | T acute lymphoblastic leukemia | MNDR-E-MI-27793 |
MNDR | hsa-miR-20a-5p | Acute t cell leukemia | MNDR-E-MI-27794 |
MNDR | hsa-miR-20a-5p | Pulmonary hypertension | MNDR-E-MI-27795 |
MNDR | hsa-miR-20a-5p | Adenoma | MNDR-E-MI-27796 |
MNDR | hsa-miR-20a-5p | Breast invasive carcinoma | MNDR-E-MI-27797 |
MNDR | hsa-miR-20a-5p | Early hepatocellular carcinoma | MNDR-E-MI-27798 |
MNDR | hsa-miR-20a-5p | B-cell lymphoma | MNDR-E-MI-27799 |
MNDR | hsa-miR-20a-5p | Rheumatoid arthritis | MNDR-E-MI-27800 |
MNDR | hsa-miR-20a-5p | T-cell leukemia | MNDR-E-MI-27801 |
MNDR | hsa-miR-20a-5p | Retinoblastoma | MNDR-E-MI-27802 |
MNDR | hsa-miR-20a-5p | Neuroblastoma | MNDR-E-MI-27803 |
MNDR | hsa-miR-20a-5p | Chronic myeloid leukemia | MNDR-E-MI-27804 |
MNDR | hsa-miR-20a-5p | Hodgkin disease | MNDR-E-MI-27805 |
MNDR | hsa-miR-20a-5p | Burkitt lymphoma | MNDR-E-MI-27806 |
MNDR | hsa-miR-20a-5p | Lymphosarcoma | MNDR-E-MI-27807 |
MNDR | hsa-miR-20a-5p | Neuromyelitis optica | MNDR-E-MI-27808 |
MNDR | hsa-miR-20a-5p | Psoriasis | MNDR-E-MI-27809 |
MNDR | hsa-miR-20a-5p | Acute myelogenous leukemia | MNDR-E-MI-27810 |
MNDR | hsa-miR-20a-5p | Colorectal cancer | MNDR-E-MI-27811 |
MNDR | hsa-miR-20a-5p | Multiple myeloma | MNDR-E-MI-27812 |
MNDR | hsa-miR-20a-5p | Acute lymphocytic leukemia | MNDR-E-MI-27813 |
MNDR | hsa-miR-20a-5p | Uterine cervical neoplasms | MNDR-E-MI-27814 |
MNDR | hsa-miR-20a-5p | Ependymoma | MNDR-E-MI-27815 |
MNDR | hsa-miR-20a-5p | Nasopharyngeal cancer | MNDR-E-MI-27816 |
MNDR | hsa-miR-20a-5p | Prostatic neoplasms | MNDR-E-MI-27817 |
MNDR | hsa-miR-20a-5p | Pseudorabies | MNDR-E-MI-27818 |
MNDR | hsa-miR-20a-5p | Arsenic poisoning | MNDR-E-MI-27819 |
MNDR | hsa-miR-20a-5p | Stroke lacunar | MNDR-E-MI-27820 |
MNDR | hsa-miR-20a-5p | Duke C | MNDR-E-MI-27821 |
MNDR | hsa-miR-20a-5p | High grade dysplastic nodule | MNDR-E-MI-27822 |
MNDR | hsa-miR-20a-5p | Tubulovillous adenoma | MNDR-E-MI-27823 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABL2 | Homo sapiens | RR00027165 |
TOP